Aylin Ozsancak Ugurlu1, Samy S Sidhom2, Ali Khodabandeh3, Michael Ieong4, Chester Mohr5, Denis Y Lin6, Irwin Buchwald7, Imad Bahhady8, John Wengryn9, Vinay Maheshwari10, Nicholas S Hill11. 1. Department of Pulmonary Disease, Başkent University, Istanbul, Turkey. 2. Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA. 3. St. Elizabeth's Medical Center, Steward Health Care, Boston, MA. 4. Boston Medical Center, Boston, MA. 5. Cape Cod Health Systems, Cape Cod Healthcare Inc, Hyannis, MA. 6. Lowell General Hospital, Lowell, MA. 7. Saints Medical Center, Lowell, MA. 8. Morton Hospital, Steward Health Care, Taunton, MA. 9. Jordan Hospital, Plymouth, MA. 10. Pulmonary Associates, Newark, DE. 11. Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA. Electronic address: nhill@tuftsmedicalcenter.org.
Abstract
BACKGROUND: This study determined actual utilization rates and outcomes of noninvasive positive pressure ventilation (NIV) at selected hospitals that had participated in a prior survey on NIV use. METHODS: This observational cohort study, based at eight acute care hospitals in Massachusetts, focused on all adult patients requiring ventilatory support for acute respiratory failure during predetermined time intervals. RESULTS: Of 548 ventilator starts, 337 (61.5%) were for invasive mechanical ventilation and 211 (38.5%) were for NIV, with an overall NIV success rate of 73.9% (ie, avoidance of intubation or death while on NIV or within 48 h of discontinuation). Causal diagnoses for respiratory failure were classified as (I) acute-on-chronic lung disease (23.5%), (II) acute de novo respiratory failure (17.9%), (III) neurologic disorders (19%), (IV) cardiogenic pulmonary edema (16.8%), (V) cardiopulmonary arrest (12.2%), and (VI) others (10.6%). NIV use and success rates for each of the causal diagnoses were, respectively, (I) 76.7% and 75.8%, (II) 37.8% and 62.2%, (III) 1.9% and 100%, (IV) 68.5% and 79.4%, (V) none, and (VI) 17.2% and 60%. Hospital mortality rate was higher in patients with invasive mechanical ventilation than in patients with NIV (30.3% vs 16.6%, P < .001). CONCLUSIONS: NIV occupies an important role in the management of acute respiratory failure in acute care hospitals in selected US hospitals and is being used for a large majority of patients with acute-on-chronic respiratory failure and acute cardiogenic pulmonary edema. NIV use appears to have increased substantially in selected US hospitals over the past decade. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00458926; URL: www.clinicaltrials.gov.
BACKGROUND: This study determined actual utilization rates and outcomes of noninvasive positive pressure ventilation (NIV) at selected hospitals that had participated in a prior survey on NIV use. METHODS: This observational cohort study, based at eight acute care hospitals in Massachusetts, focused on all adult patients requiring ventilatory support for acute respiratory failure during predetermined time intervals. RESULTS: Of 548 ventilator starts, 337 (61.5%) were for invasive mechanical ventilation and 211 (38.5%) were for NIV, with an overall NIV success rate of 73.9% (ie, avoidance of intubation or death while on NIV or within 48 h of discontinuation). Causal diagnoses for respiratory failure were classified as (I) acute-on-chronic lung disease (23.5%), (II) acute de novo respiratory failure (17.9%), (III) neurologic disorders (19%), (IV) cardiogenic pulmonary edema (16.8%), (V) cardiopulmonary arrest (12.2%), and (VI) others (10.6%). NIV use and success rates for each of the causal diagnoses were, respectively, (I) 76.7% and 75.8%, (II) 37.8% and 62.2%, (III) 1.9% and 100%, (IV) 68.5% and 79.4%, (V) none, and (VI) 17.2% and 60%. Hospital mortality rate was higher in patients with invasive mechanical ventilation than in patients with NIV (30.3% vs 16.6%, P < .001). CONCLUSIONS: NIV occupies an important role in the management of acute respiratory failure in acute care hospitals in selected US hospitals and is being used for a large majority of patients with acute-on-chronic respiratory failure and acute cardiogenic pulmonary edema. NIV use appears to have increased substantially in selected US hospitals over the past decade. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00458926; URL: www.clinicaltrials.gov.
Authors: Genevieve Christina Digby; Sean P Keenan; Christopher M Parker; Tasnim Sinuff; Karen E Burns; Sangeeta Mehta; Juan J Ronco; Demetrios J Kutsogiannis; Louise Rose; Najib T Ayas; Luc R Berthiaume; Christine L D'Arsigny; Daniel E Stollery; John Muscedere Journal: Can Respir J Date: 2015-10-15 Impact factor: 2.409
Authors: Thomas S Valley; Allan J Walkey; Peter K Lindenauer; Renda Soylemez Wiener; Colin R Cooke Journal: Crit Care Med Date: 2017-03 Impact factor: 7.598
Authors: Aylin Ozsancak Ugurlu; Samy S Sidhom; Ali Khodabandeh; Michael Ieong; Chester Mohr; Denis Y Lin; Irwin Buchwald; Imad Bahhady; John Wengryn; Vinay Maheshwari; Nicholas S Hill Journal: Lung Date: 2015-07-26 Impact factor: 2.584
Authors: Mihaela S Stefan; Penelope S Pekow; Meng-Shiou Shieh; Nicholas S Hill; Michael B Rothberg; Kimberly A Fisher; Peter K Lindenauer Journal: Crit Care Med Date: 2017-01 Impact factor: 7.598
Authors: Damien Contou; Chiara Fragnoli; Ana Córdoba-Izquierdo; Florence Boissier; Christian Brun-Buisson; Arnaud W Thille Journal: Ann Intensive Care Date: 2015-06-07 Impact factor: 6.925
Authors: Diego Martinez-Urbistondo; Félix Alegre; Francisco Carmona-Torre; Ana Huerta; Nerea Fernandez-Ros; Manuel Fortún Landecho; Alberto García-Mouriz; Jorge M Núñez-Córdoba; Nicolás García; Jorge Quiroga; Juan Felipe Lucena Journal: PLoS One Date: 2015-10-05 Impact factor: 3.240